BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cobra Biologics Ltd. Expands Antibody GMP Production Capacity


10/28/2013 9:41:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

28 October 2013: Cobra Biologics has announced the installation of a new state-of-the-art 1000L HyClone Single-Use Bioreactor (SUB) at the company’s centre of excellence for mammalian antibody and recombinant protein production. This development represents the latest roll out in Cobra’s on-going expansion plans. Installation of the 1000L disposable bioreactor has been carried out in response to strong customer demand, including securing a new contract with a longstanding North American customer.

The investment accompanies the success of Cobra achieving of a ten-fold increase in antibody business over the course of the last two years and Cobra’s continuing commitment to single-use disposable technologies dedicated to meeting both customer and regulatory stipulations. Installing the technology forms part of an investment plan, rolled out across all three of the company’s production sites in response to increased demand for contract manufacturing services and the drive to be a trusted supplier of commercial antibodies and recombinant proteins.

Peter Coleman, CEO of Cobra Biologics, remarked: “Antibody and other recombinant protein production has been a strong growth area for our specialised manufacturing site. Cobra’s maxXpress cell line development and comprehensive analytics services are proving to be very attractive to customers. Demand is such that we have the confidence to invest for the future and we see this as just a stepping stone in the expansion of our capabilities at all three Cobra facilities”.

Cobra’s expansion began with the acquisition of a purpose built aseptic manufacturing facility in 2011, providing fill and finish services for pre-filled syringes, vials and freeze drying / lyophilisation for biologics and pharmaceuticals. The Thermo Scientific™ 1000L HyClone SUB, purchased through Finesse Solutions Inc., marks a continuation of the company’s strategy for sustained growth.

Brandon Pence, Global Director of Marketing Cell Culture and BioProcessing at Thermo Fisher Scientific, commented: “We are delighted to partner with Cobra Biologics in their continued expansion of their commercial operations. The combination of our application-focused design and collaborative approach to working with customers makes the Thermo Scientific Single-Use Bioreactor the system of choice for more than 85% of the top biopharma companies. Cobra’s decision to incorporate our industry-proven design will enable the company to confidently provide consistent and high quality manufacturing services to its biotech and biopharma customers.”

Barbara Paldus, CEO at Finesse, said: “Cobra is capitalizing on the flexibility afforded by Finesse controllers for single-use bioreactors, to provide innovative bio-process solutions for established as well as development-stage biopharmaceutical companies. The addition of a 1000L vessel to the existing 50L and 250L Finesse control platform will present customers with a highly capable, scalable, and robust DeltaV-based cGMP bio-processing solution.”

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com.

About Cobra Biologics

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.

For more information please visit: www.cobrabio.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES